Empagliflozin And Metformin

Introduction Overview

Generic Name

empagliflozin and metformin

Brand Name

Synjardy

Dosage Form

Immediate-release and extended-release oral tablets

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption: Synjardy is a fixed-dose combination containing empagliflozin and metformin administered orally. Empagliflozin is rapidly absorbed following oral administration with peak plasma concentrations achieved approximately 1.5 hours post-dose. Metformin is absorbed primarily in the small intestine, with bioavailability ranging from 50 to 60%. Food intake does not significantly affect the extent of metformin absorption, but it may delay the time to peak concentration. The extended-release formulation permits gradual release and absorption over 24 hours, improving gastrointestinal tolerability.

Distribution: Empagliflozin demonstrates moderate plasma protein binding (~86%), primarily to albumin, facilitating distribution into tissues. Metformin exhibits minimal plasma protein binding (<20%) and distributes widely into body tissues, including erythrocytes and the gastrointestinal tract. The volume of distribution for metformin ranges between 63 to 276 liters, reflecting widespread tissue uptake. Both drugs do not substantially cross the blood-brain barrier.

Metabolism: Empagliflozin undergoes minimal metabolism, primarily through glucuronidation catalyzed by uridine diphosphate-glucuronosyltransferase (UGT) enzymes UGT2B7, UGT1A3, UGT1A8, and UGT1A9, forming inactive metabolites. Metformin is not metabolized significantly, exhibiting renal elimination of the unchanged compound as the primary route of clearance. This lack of hepatic metabolism reduces the potential for metabolic drug-drug interactions.

Elimination: Empagliflozin is eliminated via renal and fecal routes, with approximately 54% recovered in urine and 41% in feces, predominantly as unchanged drug and glucuronide metabolites. The elimination half-life of empagliflozin ranges from 12 to 13 hours enabling once daily dosing in extended-release formulations. Metformin is eliminated almost exclusively by renal excretion through active tubular secretion and glomerular filtration, with an elimination half-life of approximately 4 to 8.7 hours. Renal impairment significantly alters metformin clearance, increasing risk for accumulation and adverse effects like lactic acidosis. Therefore, renal function monitoring is essential during Synjardy therapy.

Dosage Forms

Available Dosage Forms: Synjardy is available as fixed-dose combination immediate-release tablets and extended-release tablets. The immediate-release tablets come in various strengths combining empagliflozin and metformin, commonly including empagliflozin 10 mg or 12.5 mg with metformin 500 mg or 850 mg or 1000 mg. Extended-release tablets are formulated for once-daily administration with strengths such as empagliflozin 10 mg plus metformin extended-release 500 mg, 850 mg, or 1000 mg.

Dosages for Adults and Adolescents: The initial dosing generally starts with empagliflozin 10 mg combined with a total daily metformin dose similar to the patient's prior regimen. Immediate-release tablets are administered twice daily, divided equally; extended-release tablets are administered once daily with meals. Dosage titration is individualized based on glycemic response and tolerability, with a maximum empagliflozin dose of 25 mg per day and metformin dosing up to 2000 mg per day. Use in adolescents aged 10 years and older is approved, with dosing adjustments based on efficacy and side effect profiles.

Specific Patient Populations: Dosage adjustment is critical in patients with renal impairment; Synjardy is contraindicated in moderate to severe renal dysfunction or dialysis patients due to increased risk of metformin accumulation and lactic acidosis. In geriatric patients (65 years and older), careful dose titration and monitoring are necessary considering comorbidities and renal function decline. Use during pregnancy is contraindicated in the second and third trimesters due to potential fetal risks. Breastfeeding is not recommended during Synjardy therapy. Adjustments during concurrent use of insulin or insulin secretagogues may be required to reduce hypoglycemia risk.

Mechanism Of Action

Synjardy combines empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with metformin, a biguanide, providing complementary mechanisms to reduce hyperglycemia in type 2 diabetes mellitus. Empagliflozin acts at the proximal renal tubules to inhibit SGLT2, reducing glucose reabsorption and promoting urinary glucose excretion. This leads to decreased plasma glucose levels independent of insulin secretion or action, thereby lowering blood sugar and reducing renal glucose burden.

Metformin primarily acts by inhibiting hepatic gluconeogenesis, decreasing endogenous glucose production by the liver. It also enhances peripheral glucose uptake and utilization, particularly in skeletal muscle, and decreases intestinal absorption of glucose. Metformin improves insulin sensitivity without causing insulin release, thus reducing hyperglycemia without significant risk of hypoglycemia when used alone.

At the molecular level, metformin activates AMP-activated protein kinase (AMPK), leading to suppressed expression of gluconeogenic enzymes and enhancement of insulin signaling pathways. Empagliflozin’s reduction in glucose reabsorption not only lowers plasma glucose but also induces osmotic diuresis, which can contribute to reductions in blood pressure and body weight, beneficial for cardiovascular risk management.

Clinical studies have demonstrated that the empagliflozin-metformin combination provides superior glycemic control compared to either agent alone, with added benefits in cardiovascular risk reduction in patients with established heart disease. Their complementary modes of action address multiple pathophysiological defects in type 2 diabetes, making Synjardy a potent therapeutic option.

Pharmacological Actions

Inhibition of renal glucose reabsorption by empagliflozin via SGLT2 blockade.
Reduction of hepatic gluconeogenesis and glucose output by metformin.
Improvement of peripheral insulin sensitivity and glucose uptake primarily by metformin.
Promotion of urinary glucose excretion leading to glycemic control.
Osmotic diuresis and mild natriuresis associated with empagliflozin, reducing blood pressure.
Weight reduction effects due to caloric loss through glycosuria induced by empagliflozin.
Activation of AMPK pathway by metformin, modulating metabolic enzymes and insulin signaling.
Contribution to cardiovascular risk reduction in type 2 diabetes patients with established cardiovascular disease.
Synergistic effects on glycemic control by combining two complementary mechanisms.
Minimal risk of hypoglycemia when used as monotherapy or in combination without insulin or secretagogues.
Lack of significant hepatic metabolism reduces potential for drug interactions.
Improvement in glycemic parameters including HbA1c and fasting plasma glucose.
Reduction in markers of insulin resistance observed with metformin component.
Potential renal protective effects attributed to improved glycemic and hemodynamic profiles.
Improved endothelial function and decreased oxidative stress associated with combined therapy.

Therapeutic Or Clinical Uses

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Management of blood glucose in adolescents aged 10 years and older with type 2 diabetes.
Reduction of risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Part of combination therapy in patients inadequately controlled on metformin or empagliflozin monotherapy.
Alternative to intensify therapy in patients failing single oral antidiabetic treatment.
Potential use in patients with obesity-associated type 2 diabetes for weight benefits.
Reduction of fasting plasma glucose and postprandial glucose excursions.
Improvement in insulin sensitivity and beta cell function preservation.
Utility in patients with hypertension and type 2 diabetes due to blood pressure lowering effect.
Decreased risk of hospitalization for heart failure in high-risk diabetic patients.
Long-term management option to prevent diabetes-related complications.
Use in patients intolerant to higher doses of monotherapy due to gastrointestinal side effects.
Adjunct therapy in patients requiring improved metabolic control without hypoglycemia risk.
Reduction in macrovascular and microvascular complications associated with diabetes.
Improvement of patient adherence due to fixed-dose combination formulation.

Side Or Adverse Effects

Risk of lactic acidosis, a potentially fatal condition requiring emergency intervention.
Genital mycotic infections including yeast infections in women and balanitis in men.
Urinary tract infections, including bladder infections presenting with dysuria and urgency.
Hypoglycemia when used in combination with insulin or insulin secretagogues.
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, flatulence, and indigestion.
Dehydration-related symptoms including dizziness, hypotension, and confusion.
Headache and general weakness reported in some patients.
Increased risk of ketoacidosis even with normal or mildly elevated blood glucose levels.
Potential for acute kidney injury, especially in volume-depleted patients or those with renal impairment.
Possible vitamin B12 deficiency with prolonged metformin use.
Rare allergic reactions including urticaria, angioedema, and anaphylaxis.
Electrolyte imbalances such as increased serum potassium in susceptible individuals.
Increased risk of bone fractures has been a concern with some SGLT2 inhibitors, though data for empagliflozin is limited.
Risk of hypotension, especially in elderly patients or those on antihypertensives.
Common cold-like symptoms including sore throat and nasal congestion.

Precautions

Assess renal function prior to initiation and periodically during therapy; contraindicated in moderate to severe renal impairment.
Monitor for signs and symptoms of lactic acidosis, especially in conditions predisposing to hypoxia or impaired renal function.
Avoid use in patients with diabetic ketoacidosis or metabolic acidosis.
Use caution in elderly patients due to increased risk of volume depletion and renal impairment.
Temporary discontinuation may be necessary before radiologic studies involving iodine-containing contrast agents.
Educate patients regarding recognition of genital infections and prompt reporting.
Adjust doses when used concomitantly with insulin or insulin secretagogues to prevent hypoglycemia.
Monitor for symptoms indicative of urinary tract infections and treat promptly.
Use caution in patients with hepatic impairment due to altered drug clearance.
Advise patients to maintain adequate hydration to minimize hypotension and renal adverse effects.
Metformin component may cause vitamin B12 deficiency; periodic monitoring is recommended.
Avoid excessive alcohol intake due to increased risk of lactic acidosis.
Evaluate for potential drug interactions that may alter efficacy or increase adverse effects.
Pregnancy use limited; contraindicated in second and third trimesters.
Advise female patients about the potential of increased ovulation and unintended pregnancy risk due to metformin.

Warnings

Serious risk of lactic acidosis with symptoms including muscle pain, weakness, respiratory difficulty, abdominal symptoms, slow or irregular heartbeat, dizziness, and fatigue.
Risk of serious genital infections that can rapidly progress and require immediate medical attention.
Not for use in patients with moderate to severe kidney disease or those undergoing dialysis.
Patients should temporarily discontinue Synjardy before any radiologic study involving iodinated contrast to reduce risk of renal failure and lactic acidosis.
May cause ketoacidosis even when blood glucose is not significantly elevated; monitor ketone levels if clinically indicated.
Use caution when employed in patients with congestive heart failure, recent heart attack, or stroke due to altered hemodynamics.
May cause dehydration leading to hypotension, particularly in older adults or those on diuretics.
Avoid use during second and third trimesters of pregnancy due to potential fetal harm.
Breastfeeding is not recommended during therapy due to unknown excretion into breast milk.
Potential for hypoglycemia when coadministered with other antidiabetic agents.
Synjardy may interfere with results of certain lab tests; inform healthcare providers about use.
Risk of gastrointestinal adverse reactions which may affect patient compliance.
Use cautiously in patients on low salt diet.
Patients should be informed about proper dosing and the importance of adherence to diet and exercise regimens.
Avoid alcohol consumption to decrease lactic acidosis risk.

Contraindication

Known hypersensitivity to empagliflozin, metformin, or any component of Synjardy.
Severe renal impairment (eGFR <30 mL/min/1.73m²), end-stage renal disease, or patients on dialysis.
Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Severe hepatic impairment associated with risk of lactic acidosis.
Conditions predisposing to hypoxia such as acute congestive heart failure, recent myocardial infarction, or respiratory failure.
Use during the second and third trimesters of pregnancy.
Known history of lactic acidosis related to previous metformin therapy.
Patients undergoing radiologic studies involving intravascular iodinated contrast media unless temporarily discontinued.
Type 1 diabetes mellitus, as Synjardy is not indicated for insulin-dependent diabetes.
Concomitant use with other SGLT2 inhibitors or another metformin-containing product to avoid overdose.
History of severe allergic reactions to any ingredient in Synjardy.
Patients with known severe gastrointestinal diseases affecting absorption or motility.
Patients with acute conditions such as severe infections, trauma, or surgical procedures increasing risk for lactic acidosis.
Use in pediatric patients under 10 years old due to lack of safety data.

Drug Interactions

Concomitant use with insulin or insulin secretagogues increases risk of hypoglycemia; dose adjustments may be necessary.
Diuretics (water pills) may predispose to volume depletion and hypotension when combined with Synjardy.
Drugs that impair renal function, such as NSAIDs or ACE inhibitors, may increase the risk of lactic acidosis with metformin.
Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine, ranitidine) may increase plasma metformin concentrations.
Substances affecting renal function or tubular secretion may alter metformin clearance.
Drugs slowing gastrointestinal motility may affect absorption of metformin.
Certain medications may interfere with glucose metabolism, impacting glycemic control when combined.
Alcohol may potentiate the effect of metformin on lactate metabolism, increasing lactic acidosis risk.
Use with iodinated contrast media may impair renal function and increase lactic acidosis risk; temporary discontinuation is advised.
Co-administration with drugs inducing uridine diphosphate-glucuronosyltransferase (UGT) enzymes could potentially increase empagliflozin metabolism, reducing efficacy.
Combination with SGLT2 inhibitors other than empagliflozin is not recommended to avoid additive effects.
Medications affecting blood pressure or volume status should be monitored carefully during Synjardy therapy.
Concomitant use of drugs that cause hypoglycemia or impact glucose metabolism requires close monitoring.
Supplements such as vitamin B12 may be necessary due to metformin-associated deficiency.
Potential interactions with herbal products and over-the-counter drugs should be assessed.

Preparations Of The Drug

Immediate-release tablets containing empagliflozin 10 mg with metformin 500 mg or 850 mg or 1000 mg.
Extended-release (XR) tablets containing empagliflozin 10 mg with metformin XR 500 mg, 850 mg, or 1000 mg.
Fixed-dose combination tablets designed for twice daily dosing (immediate-release) and once daily dosing (extended-release).
Available strengths include empagliflozin-metformin 10 mg/500 mg, 10 mg/850 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, etc., varying by formulation and region.
Supplied in blister packs or bottles to ensure dose accuracy and patient compliance.
Formulations manufactured to ensure stability and uniform release characteristics.
Not available in oral liquid form; administration limited to oral tablets.
Storage at controlled room temperature away from moisture and heat is recommended.
Packaging includes medication guides to inform patients about proper administration and warnings.
Extended-release tablets are to be swallowed whole without crushing or chewing to maintain release properties.
Available under brand names Synjardy and Synjardy XR.
Formulations approved for use in patients aged 10 years and older with type 2 diabetes.
Manufactured according to regulatory standards for quality and bioequivalence.
Prescribed only under medical supervision with dosing individualized based on patient needs.
Available through prescription with patient counseling on adherence and lifestyle modification.